1 Min Read
Feb 28 (Reuters) - Immune Pharmaceuticals Inc
* Immune Pharmaceuticals reports encouraging preliminary data with bertilimumab in an open label phase 2 study in the rare dermatological auto-immune disease, bullous pemphigoid
* Says no significant adverse events were reported.
* Immune Pharmaceuticals - based on these preliminary results, company has also submitted a request for orphan drug designation for bertilimumab in BP Source text for Eikon: Further company coverage: